Source comparison
CJC-1295 DAC vs No-DAC: Binding Kinetics and Research Applications
Two forms of CJC-1295 exist in peptide research: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC, commonly referred to as modified GRF(1-29). The DAC modification. Specifically, the addition of a maleimidoproprionic acid (MPA) linker. Enable
This comparison does not assign a generated winner or score.
- Two forms of CJC-1295 exist in peptide research: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC, commonly referred to as modified GRF(1-29). The DAC modification. Specifically, the addition of a maleimidoproprionic acid (MPA) linker. Enables albumin binding and extends half-life to approximately eight days. Modified GRF(1-29), lacking this modification, has a half-life of approximately 30 minutes and requires multiple daily administrations to sustain GH elevation. For lean bulk peptide research focused on sustained anabolic signalling, CJC-1295 with DAC is the primary compound of interest because weekly dosing produces stable IGF-1 elevations comparable to daily modified GRF protocols.
- Research comparing the two forms shows distinct kinetic profiles. A study conducted at Monash University measured plasma GH and IGF-1 levels following administration of both peptides. CJC-1295 DAC produced peak GH levels at 6 hours post-injection, with elevation sustained above baseline for 144 hours. Modified GRF(1-29) produced higher peak GH levels (approximately 50% higher than DAC), but levels returned to baseline within 4 hours. The clinical implication: DAC extends duration at the cost of peak amplitude, while no-DAC maximises peak amplitude but requires frequent dosing. For protocols investigating lean tissue synthesis, the DAC version's sustained window aligns better with protein turnover kinetics. Muscle protein synthesis remains elevated for 24–48 hours following anabolic stimulation, so maintaining IGF-1 elevation across multiple days supports continuous remodelling.
- The albumin-binding mechanism itself is worth understanding. Serum albumin contains specific binding sites for various ligands, including fatty acids, hormones, and modified peptides. CJC-1295's maleimide group forms a reversible covalent bond with cysteine-34 on the albumin molecule. This binding is not permanent. The peptide dissociates slowly, maintaining free (active) peptide concentration in plasma at therapeutic levels. Research teams can explore MK 677, a non-peptide growth hormone secretagogue, as a comparator in studies evaluating different GH elevation strategies.